FI920206A0 - Medicinsk anvaendning, medicinskt foerfarande och preparat. - Google Patents

Medicinsk anvaendning, medicinskt foerfarande och preparat.

Info

Publication number
FI920206A0
FI920206A0 FI920206A FI920206A FI920206A0 FI 920206 A0 FI920206 A0 FI 920206A0 FI 920206 A FI920206 A FI 920206A FI 920206 A FI920206 A FI 920206A FI 920206 A0 FI920206 A0 FI 920206A0
Authority
FI
Finland
Prior art keywords
pct
antibiotic
medicinskt
medicinsk
preparat
Prior art date
Application number
FI920206A
Other languages
English (en)
Inventor
Pekka Untamo Heino
Original Assignee
Pekka Untamo Heino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pekka Untamo Heino filed Critical Pekka Untamo Heino
Priority to FI920206A priority Critical patent/FI920206A0/fi
Publication of FI920206A0 publication Critical patent/FI920206A0/fi
Priority to DE69322659T priority patent/DE69322659T2/de
Priority to AT93902271T priority patent/ATE174513T1/de
Priority to DK93902271T priority patent/DK0671942T3/da
Priority to PCT/FI1993/000016 priority patent/WO1993013795A1/en
Priority to US08/256,508 priority patent/US5607671A/en
Priority to ES93902271T priority patent/ES2129078T3/es
Priority to EP93902271A priority patent/EP0671942B1/en
Priority to GR990400783T priority patent/GR3029699T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004—Amidase (3.5.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
FI920206A 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat. FI920206A0 (fi)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FI920206A FI920206A0 (fi) 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat.
DE69322659T DE69322659T2 (de) 1992-01-17 1993-01-18 Pharmazeutische zubereitung enthaltend eine beta-lactam antibiotikum abbauende verbindung, und deren verwendung
AT93902271T ATE174513T1 (de) 1992-01-17 1993-01-18 Pharmazeutische zubereitung enthaltend eine beta-lactam antibiotikum abbauende verbindung, und deren verwendung
DK93902271T DK0671942T3 (da) 1992-01-17 1993-01-18 Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf
PCT/FI1993/000016 WO1993013795A1 (en) 1992-01-17 1993-01-18 Medical use, a medical method and a pharmaceutical preparation
US08/256,508 US5607671A (en) 1992-01-17 1993-01-18 Medical use, a medical method and a pharmaceutical preparation
ES93902271T ES2129078T3 (es) 1992-01-17 1993-01-18 Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.
EP93902271A EP0671942B1 (en) 1992-01-17 1993-01-18 Pharmaceutical preparation comprising a beta-lactam antibiotic degrading compound, and use thereof
GR990400783T GR3029699T3 (en) 1992-01-17 1999-03-16 Medical use, a medical method and a pharmaceutical preparation.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI920206A FI920206A0 (fi) 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat.

Publications (1)

Publication Number Publication Date
FI920206A0 true FI920206A0 (fi) 1992-01-17

Family

ID=8534042

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920206A FI920206A0 (fi) 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat.

Country Status (9)

Country Link
US (1) US5607671A (fi)
EP (1) EP0671942B1 (fi)
AT (1) ATE174513T1 (fi)
DE (1) DE69322659T2 (fi)
DK (1) DK0671942T3 (fi)
ES (1) ES2129078T3 (fi)
FI (1) FI920206A0 (fi)
GR (1) GR3029699T3 (fi)
WO (1) WO1993013795A1 (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711128C (en) * 1996-05-09 2002-11-07 Sankyo Company Limited Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
FI20020332A0 (fi) * 2002-02-20 2002-02-20 Heino Pekka Untamo Valmiste ja menetelmä painon pudottamiseksi
FR2843301B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
CA2688721A1 (en) * 2007-05-21 2008-11-27 Phenomix Corporation Stable pharmaceutical formulation for a dpp-iv inhibitor
ITBO20080297A1 (it) * 2008-05-16 2009-11-17 Archimede R & D S R L Composizione enzimatica per ridurre il rilascio di principi attivi farmaceutici nell'ambiente.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
ITMI20121715A1 (it) * 2012-10-11 2014-04-12 Bioikos Ambiente S R L Composizioni farmaceutiche con ridotto impatto ambientale
BR112016023360B1 (pt) 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
JP6672277B2 (ja) * 2014-10-08 2020-04-01 シンセティック・バイオロジクス・インコーポレイテッド ベータラクタマーゼ製剤およびその使用
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US20160250304A1 (en) 2015-02-23 2016-09-01 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
KR20170122776A (ko) 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
US10988749B2 (en) 2016-02-23 2021-04-27 Da Volterra Beta-lactamase variants
PT3420078T (pt) 2016-02-23 2022-07-13 Da Volterra Variantes da beta-lactamase
CN111247246A (zh) 2017-10-25 2020-06-05 达·沃尔泰拉公司 β-内酰胺酶变体
EP3965804A4 (en) * 2019-05-06 2023-05-24 Synthetic Biologics, Inc. BETA-LACTAMASE COMPOSITIONS FOR THE TREATMENT OF GRAFT VERSUS HOST REACTION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613624B1 (fr) * 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CS275231B2 (en) * 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle

Also Published As

Publication number Publication date
EP0671942B1 (en) 1998-12-16
DK0671942T3 (da) 1999-08-23
ES2129078T3 (es) 1999-06-01
DE69322659T2 (de) 2000-01-05
DE69322659D1 (de) 1999-01-28
ATE174513T1 (de) 1999-01-15
GR3029699T3 (en) 1999-06-30
US5607671A (en) 1997-03-04
WO1993013795A1 (en) 1993-07-22
EP0671942A1 (en) 1995-09-20

Similar Documents

Publication Publication Date Title
FI920206A0 (fi) Medicinsk anvaendning, medicinskt foerfarande och preparat.
Suh et al. Quinolones
MY124714A (en) Enzyme treatment
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
ATE355076T1 (de) Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen
NO20014507L (no) Legemiddel for behandling av sukkersyke
DE69521994T2 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
FR2700117B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
HUP9904308A2 (hu) A mupirocin alkalmazása a nasopharynxnak patogén organizmusokkal történő kolonizációjához társuló bakteriális fertőzések kezelésére szolgáló gyógyszerkészítmény előállítására
ATE337712T1 (de) Zusammensetzung zur intestinalen verabreichung
RU94016167A (ru) Фармацевтическая композиция, способы доставки биологически активного вещества, способы лечения, способы стимулирования
ME00578A (en) Use of gastrointestinal lipase inhibitors
DE69622855T2 (de) Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten
DE69723864D1 (en) Ethyliden-derivate tricyclyscher carbapenems
Rosenberg et al. Antibiotic TA: an adherent antibiotic
CN1285745A (zh) 酶前体药物作为抗感染剂的应用
DE69933925D1 (de) Verbesserte methode zur eradikation von helicobacter pylori
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
RU95118193A (ru) Штамм бактерий bifidobacterium coturnix, используемый для приготовления пробиотического препарата для птицеводства и ветеринарии
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic
UA30011A (uk) Спосіб профілактики гострих стресових уражень шлунково-кишкового тракту після порожнинних оперативних втручань